Veracyte (VCYT) EPS (Weighted Average and Diluted) (2019 - 2026)

Veracyte has disclosed EPS (Weighted Average and Diluted) across 8 years of filings, most recently posting $0.35 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.35, up 288.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.08 (up 163.41% YoY), and the FY2025 annual result was $0.82, up 164.52% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.35 for Q1 2026 at Veracyte, down from $0.5 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.5 in Q4 2025 to a low of -$0.41 in Q3 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.02 (2024), against an average of -$0.0.
• Across the five-year window, EPS (Weighted Average and Diluted) sank 660.0% in 2023 and jumped 733.33% in 2025, its largest moves.
• Veracyte's EPS (Weighted Average and Diluted) stood at -$0.05 in 2022, then tumbled by 660.0% to -$0.38 in 2023, then surged by 115.79% to $0.06 in 2024, then surged by 733.33% to $0.5 in 2025, then dropped by 30.0% to $0.35 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.35 (Q1 2026), $0.5 (Q4 2025), and $0.24 (Q3 2025), per Business Quant data.